Subjective Tinnitus
Investigational use for chronic subjective tinnitus; case-series evidence for THI score improvement. Mechanism speculative.
Patient Summary
- Is this FDA-cleared for this use?
- Not FDA-cleared for tinnitus. FDA cleared medicinal leeches only for venous congestion in microsurgical reconstruction (K040187, 2004). Use for subjective tinnitus is investigational.
- What evidence exists?
- Tier C (investigational). Small case reports describe subjective improvement in tinnitus loudness or distress in some patients. There are no randomized controlled trials. Tinnitus has high placebo response. Evidence-based management focuses on hearing-loss correction (hearing aids), cognitive-behavioral therapy, tinnitus retraining therapy, and sound therapy. Pulsatile tinnitus is a separate condition that requires vascular workup.
- Main risks
- Bleeding from bite sites for 6 to 24 hours after detachment (placement around the ear, mastoid, or upper neck)
- Bruising and tenderness near the ear and neck for 5 to 10 days
- Itching and irritation at bite sites for days to weeks
- Local skin infection or, rarely, Aeromonas infection (particular concern near ear canal)
- Allergic reaction to leech saliva (uncommon)
- Temporary worsening of tinnitus or new dizziness for 1 to 2 days
- Small permanent scars at bite sites
- Who should not consider this
- Patients on blood thinners (warfarin INR >2.0, DOACs, heparin)
- Patients with hemophilia or other bleeding disorders
- Patients with severe anemia (Hb <10 g/dL)
- Patients with pulsatile tinnitus (needs vascular workup, not leech therapy)
- Patients with unilateral tinnitus not yet evaluated by ENT/MRI (rule out acoustic neuroma)
- Patients with active outer or middle ear infection
- Patients with a weakened immune system
- What to ask your clinician
- Have I had an audiogram and ENT evaluation?
- Have I had imaging (MRI) if my tinnitus is unilateral, pulsatile, or associated with neurologic symptoms?
- Have I been offered hearing aids (if hearing loss), CBT, tinnitus retraining, or sound therapy?
- What evidence supports leech therapy for tinnitus specifically?
- What is the realistic chance of benefit, given high placebo response?
- What is the practitioner's experience and Aeromonas-prevention plan?
- What is the cost?
- When to seek urgent care
- Sudden hearing loss in one or both ears (sudden sensorineural hearing loss is an emergency)
- New severe vertigo, gait imbalance, weakness, numbness, or speech change
- Spreading redness, warmth, pus, or red streaks near the ear (cellulitis)
- Bleeding from a bite site lasting more than 24 to 48 hours
- Fever above 38.0 C / 100.4 F or chills
- Hives, throat tightness, or breathing difficulty
What this does NOT mean
- This is not FDA-cleared for tinnitus.
- Case reports do NOT establish efficacy beyond placebo, especially in tinnitus where placebo response is high.
- Mechanism rationale (venous decongestion, local anti-inflammation) does NOT establish clinical efficacy.
- Leech therapy will NOT cure tinnitus and does NOT address underlying causes.
- Leech therapy is not a substitute for ENT evaluation, hearing-aid fitting, or behavioral therapies.
Safety cross-references
Clinical Profile
- Category
- ent
- ICD-10
- H93.11, H93.12, H93.13, H93.19
- Safety tier
- low
Evidence Summary
The clinical evidence for leech therapy in tinnitus is minimal and dated. A historical study (Seleznev et al., 1992) reported symptomatic benefit in tinnitus caused by inner-ear affections using medicinal leeches, with diluted leech saliva delivered to the mastoid region; beyond this the literature consists only of naturopathy notes and case reports. No modern controlled trial and no validated outcome data (e.g., Tinnitus Handicap Inventory) exist, so any use remains investigational. Where attempted, leeches are placed at the mastoid, behind the ear, and on the upper trapezius, with a speculative mechanism involving cervicogenic/somatosensory or local vascular factors. Objective tinnitus (audible pulsatile tinnitus from vascular pathology or glomus tumor) requires imaging workup and is not an indication. ENT consultation is essential before any treatment.
Treatment specifics
How many leeches, where they are placed, how long a session lasts, and whether to repeat are clinical decisions made by a qualified provider under institutional protocol — not something to self-administer. Discuss the specifics with a clinician experienced in medicinal leech therapy. (Clinicians: switch the audience selector in the top bar to “Clinician” to view protocol detail.)
Key Trials
- Yildirim MA et al. (2016), n=20
Contraindications
- Active anticoagulant therapy (warfarin INR >2.0, DOACs, heparin)
- Hemophilia or other bleeding disorder
- Severe anemia (Hb <10 g/dL)
- Active bacteremia or sepsis
- Known hypersensitivity to leech salivary proteins
- Pregnancy (relative — first/third trimester)
- Immunocompromised state with severe neutropenia
- Objective pulsatile tinnitus (must rule out structural cause)
- Acute otitis media or externa
Related Conditions
Chronic Rhinosinusitis
Off-label use with one RCT showing symptom and SNOT-22 score improvement at 4 weeks in non-polypoid chronic sinusitis.
Ménière's Disease (Adjunctive)
Investigational adjunctive use for Ménière's disease; very limited evidence. Standard management (diet, betahistine, intratympanic therapy) remains primary.
Pulsatile Tinnitus (Vascular-Origin Subtype)
Investigational use for pulsatile vascular-origin tinnitus distinct from subjective tinnitus; case-report evidence only.
Meniere's Disease (Vestibular Attack Frequency)
Investigational adjunct for vestibular attack frequency reduction in definite Meniere's disease per AAO-HNS 2015 criteria; case-series evidence.